<DOC>
	<DOCNO>NCT02069834</DOCNO>
	<brief_summary>The primary objective study evaluate capacity Dolutegravir + Rilpivirine vs. continue triple combination HAART maintain plasma HIV RNA ≤ 50 copies/ml throughout 24 week patient plasma HIV RNA ≤ 50 copies/mL least 2 year conventional HAART ( 2 NNRTI + 3rd agent ) . The main secondary objective follow : - % virologic success ( plasma viral load ≤ 50 copies/mL ) W24 W48 - % patient maintain plasma viral load ≤ 50 copy / ml D0 W48 - % virological failure define two consecutive plasma viral load &gt; 50 copies/mL - Profile genotypic resistance case virological failure . The trial conduct accord design , 3 step : - Step 1 : enrollment 80 patient ( 40 arm ) - Step 2 : enrollment hold W16 data 40 patient enrol intervention arm analyze . - Step 3 : resumption completion enrollment condition resume enrollment end step 2 fulfil , i.e . percentage patient randomize intervention arm plasma viral load ≤ 50 copies/mL D0 W16 significantly &gt; 70 % , translate maximum 6 virologic failure .</brief_summary>
	<brief_title>Dolutegravir + Rilpivirine Switch Study ( DORISS )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Age ≥ 18 year HIV1 infection Treatment suppressive triple HAART ( 2 NRTI + either 1 PI/r , 1 NNRTI , INI ) , unchanged &gt; 6 month , Intraclass substitution within past 6 month consider treatment change . Plasma HIVRNA ≤ 50 copies/mL &gt; 2 year CD4 cell count &gt; 350/mm3 &gt; 6 month No prior virologic failure NNRTIcontaining INSTIcontaining ART regimen No NNRTI mutation preART genotype ( preART genotype available : NNRTI mutation DNA genotype screen ) among follow : K101E/P , E138A/G/K/Q/R/S , V179L , Y181C/I/V , Y188L , H221Y , M230I/L/V , L100I + K103N/S , L100I +K103R +V179D . No mutation ( either preART genotype DNA genotype screen ) among follow : T66K , G118R , V151L , S153F/Y , R263K , T66K + L74M , E92Q + N155H , Q148R +N155H , Q148H/K/R least one mutation L74I E138A/K/T G140A/C/S Negative HBs Ag Informed consent form sign patient investigator A specific consent pharmacokinetic substudy sign 10 patient pilot phase trial randomize Dolutegravir + Rilpivirine arm volunteer PK study Patient cover health insurance Effective contraception HIV2 infection Dialysis severe renal failure ( creatinine clearance &lt; 30 ml/min ) History decompensated liver disease History HIVassociated neurocognitive disorder AST ALT &gt; 5 x ULN Positive HBc Ac negative HBs Ac Patient receive proton pump inhibitor switch another antisecretory drug Current pregnancy breastfeed Patient involve another research preclude enrolment another trial Patient guardianship , deprive liberty court administrative decision .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Dolutegravir</keyword>
	<keyword>Rilpivirine</keyword>
	<keyword>PI- NRTI- spar ART regimen</keyword>
	<keyword>switch study</keyword>
</DOC>